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SUMMARY – The purpose of this study was to determine the efficacy of combined intravitreal 
bevacizumab and triamcinolone in the treatment of macular edema due to retinal vein occlusion. A 
prospective randomized trial was conducted in the Department of Ophthalmology, Osijek University 
Hospital Centre in Osijek including 51 patients divided into three groups depending on the drug 
received. The first group received 1.25 mg intravitreal bevacizumab, the second group received 1 mg 
intravitreal triamcinolone, and the third group received a combination of 1.25 mg bevacizumab and 1 
mg intravitreal triamcinolone on the same day. Changes in the central macular thickness, intraocular 
pressure and visual acuity were monitored during the follow up period. The retinal perfusion status was 
evaluated by fluorescein angiography. The group that received combined treatment had better outcome 
in terms of reduction of macular thickness. There was no statistically significant intraocular pressure 
elevation among the three treatment groups or within each group of patients. A positive trend regard-
ing visual improvement was observed in the group receiving combined treatment in spite of the lowest 
initial visual acuity, highest value of macular thickness and longest mean duration of symptoms. In 
conclusion, combined treatment with bevacizumab and triamcinolone for the treatment of retinal vein 
occlusion is more potent, safe, efficient and cost-effective. It can also be recommended because fewer 
injections are needed in patients undergoing treatment for macular edema.
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Introduction
Retinal vein occlusion (RVO) is the second most 
common vascular retinal disorder and one of the lead-
ing causes of visual loss in the elderly. The incidence 
varies from 0.2% to 0.8%1,2. Current treatment options 
for macular edema do not provide permanent solution 
due to frequent recurrence and persistence of the ede-
ma3. Monotherapy with intravitreal anti-vascular en-
dothelial growth factor (anti-VEGF) agents or corti-
costeroids has its limitations and side effects, i.e. short 
duration, the need for repetitive injections, risk of en-
dophthalmitis, rise of intraocular pressure (IOP), and 
cataract formation4-6. In the reference books there are 
only a few studies regarding simultaneous application 
of bevacizumab and triamcinolone for the treatment of 
macular edema following RVO. Ehrlich et al.7 used a 
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higher dose of intravitreal corticosteroid (2 mg) al-
though a dose of 1 mg showed efficacy, with better 
safety profile and lower incidence of complications8. 
The main focus of this study was to determine the ef-
ficacy and safety of a combination of bevacizumab and 
triamcinolone for the treatment of macular edema due 
to RVO.
Patients and Methods
Fifty-one patients with macular edema secondary 
to RVO were enrolled in this prospective study, out of 
which 30 (59%) women and 21 (41%) men, mean age 
70 (range 44-87) years. Informed consent was ob-
tained from each participant after detailed explanation 
of the nature and possible consequences of the study. 
The research was approved by the institutional Review 
Board of the Osijek University Hospital Centre. The 
study followed the tenets of the Declaration of Hel-
sinki.
At baseline, each patient underwent complete oph-
thalmologic examination including best corrected vi-
sual acuity (VA), biomicroscopic examination, appla-
nation tonometry, indirect ophthalmoscopy, fluoresce-
in angiography, and spectral domain optical coherence 
tomography (SD-OCT). These tests were repeated 
after intravitreal application of the drugs and at follow 
up visits after three, six and twelve months. According 
to the type of occlusion, 19 (37%) patients had central 
retinal vein occlusion (CRVO) and 32 (63%) patients 
had branch retinal vein occlusion (BRVO). They were 
randomly distributed to the drug they received. The 
type of occlusion was not a determining criterion for 
allocation to a specific group. Types of occlusion ac-
cording to groups are shown in Figure 1.
Patients were classified into three groups. The first 
group received 1.25 mg bevacizumab (group B), the 
second group received 1 mg triamcinolone (group T), 
and the third group received intravitreal combination 
of both drugs (group BT) (1.25 mg bevacizumab and 
1 mg triamcinolone). The drug was administered in the 
operating room under aseptic conditions and after in-
stillation of topical anesthetic (tetracaine 0.5% solu-
tion). The site of application was 3-4 mm from the 
limbus in the lower temporal quadrant, depending on 
the phakic status of the eye. Two different syringes 
were used in the combination treatment group, one for 
each drug. Depending on the central macular thick-
ness (CMT) measured on SD-OCT (CMT ≥250 µm) 
and the clinical finding on the fundus (residual exuda-
tion), patients were scheduled for reapplication of the 
drug. The interval between the applications was at least 
6 weeks for bevacizumab and 12 weeks for triamcino-
lone. The average monitoring period per patient was 11 
(SD ±2) months with a minimum of 3 visits, due to 
sample dissipation.
Data were analyzed by descriptive statistics and af-
ter determining distribution of the variables with Kol-
mogorov Smirnov test, nonparametric tests were used 
(Mann-Whitney U-test, Kruskal-Wallis, median test, 
Kendall’s W-test, Cochran’s Q-test). The final sample 
encompassed the patients who had minimally three 
visits, i.e. three measurements. The study was conduct-
ed on three independent samples and therefore the 
tests appropriate for independent samples were used. 
Statistical analysis was performed by using commer-
cially available SPSS. The p value of 0.05 was selected 
to determine significance of the results.
Results
The efficacy of the drug was measured primarily by 
CMT change, while the increase in IOP reflected the 
safety of treatment. The change in VA was also as-
Fig. 1. Types of occlusion in patient groups.
CRVO = central retinal vein occlusion; BRVO = branch retinal vein 
occlusion
Table 1. Ischemic and non-ischemic types of occlusion 
according to therapy groups
Group Ischemic Non-ischemic Total
Bevacizumab 1 21 22
Triamcinolone 3 9 12
Combination 7 10 17
Total 11 40 51
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Fig. 2. Visual acuity changes (Snellen visual acuity)  
in bevacizumab group.
Fig. 3. Visual acuity changes (Snellen visual acuity)  
in triamcinolone group.
Fig. 4. Visual acuity changes (Snellen visual acuity)  
in bevacizumab plus triamcinolone group.
Fig. 5. Qualitative shift in visual acuity between first 
and third visit.
VA = visual acuity
Fig. 7. Comparison of mean intraocular pressure values 
(mm Hg) among groups.
Fig. 6. Change in central macular thickness (CMT) 
across three patient groups.
  CMT (µm) 
 Bevacizumab Triamcinolone Combination
sessed as a secondary outcome. There was no statisti-
cally significant difference in age and sex among the 
groups (independent median test, p=0.656; Kruskal-
Wallis test for independent samples, p=0.758). The 
type of occlusion did not influence distribution of the 
CMT change throughout measurements on the whole 
sample. It did not affect final VA (p=0.182), CMT 
(p=0.555) or IOP changes (p=0.060) either. The lon-
gest duration of symptoms (5.3 months) was recorded 
in the BT group, whereas it was somewhat shorter in 
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the T and B groups (4.7 months in group T and 3.9 
months in group B). The ratio of ischemic to non-isch-
emic types of occlusion is shown in Table 1. Ischemic 
type was considered if the capillary occlusion area was 
greater than 10 disc diameters as documented on fluo-
rescein angiography.
A secondary outcome of the study was the change 
in VA. The distribution across the groups is shown in 
Figures 2, 3 and 4.
Distribution of VA varied among the groups (Krus-
kal-Wallis test for independent samples, p=0.024). Bev-
acizumab and the combination of both medications 
were more efficient than triamcinolone alone, while the 
B and BT groups did not differ significantly, although 
a more obvious VA improvement was recorded in BT 
group. The qualitative shift in VA should be considered 
since BT group had the lowest initial VA and highest 
CMT (Fig. 5).
The VA was stable only in BT group, i.e. there was 
no negative shift; in T group, initial VA worsened in 
60% of patients and therefore the most negative shift 
was recorded.
The primary outcome was the change in CMT. All 
three groups of patients had a significant decrease in 
CMT (Fig. 6). The combination of both medications 
was more efficient than bevacizumab (p=0.022). How-
ever, there was no statistically significant difference 
between triamcinolone and combination therapy 
(p=0.344). Group BT had the largest decrease in 
CMT. The initial average CMT was 325 µ in group B, 
506 µ in group T, and 620 µ in group BT. Following 
the third visit, the values were 316 µ in group B, 351 µ 
in group T, and 397 µ in group BT. The average initial 
CMT was 619 µ in the ischemic type and 421 µ in the 
non-ischemic type. These values were statistically sig-
nificant (p=0.023). The CMT changes across the 
groups varied significantly (p=0.026, Kruskal-Wallis 
test for independent samples).
Statistical analysis of the paired samples confirmed 
that the combination of medications was more efficient 
than bevacizumab while no difference was observed be-
tween triamcinolone and combination of medications 
regardless of better CMT improvement in BT group.
Another outcome was the effect of treatment on 
IOP. No significant IOP elevation or difference in 
IOP values across the groups was found (Fig. 7).
The highest IOP values did not exceed 27 mm Hg. 
No statistically significant difference was observed in 
IOP values between the groups BT and B. The IOP 
was 10-23 mm Hg in group B, 8-26 mm Hg in group 
T, and 10-22 mm Hg in group BT. The IOP changes 
across the groups were equally distributed (p=0.716, 
Kruskal-Wallis test for independent samples).
Patient age did not influence VA (p=0.684), CMT 
(p=0.701) or IOP (p=0.749). The average number of 
intravitreal injections was 3 in group B, 2 in group T, 
and 2 in group BT.
Discussion
Better initial VA, younger age and shorter duration 
of symptoms were recognized as positive predictive 
factors for functional improvement in BRVO9. In pre-
vious reports, 75% of patients with CRVO were re-
fractory to treatment7. In our study, patients did not 
receive intravitreal therapy (anti-VEGF or corticoste-
roids) or laser treatment prior to enrolment in the 
study. Favorable response to combination therapy de-
spite lower initial VA and higher CMT could be due 
to the residual potential of the photoreceptors, which 
are not irreversibly damaged by ischemia. A large pro-
portion of patients had cataract at baseline (63.6% in 
group B, 69.2% in group T, and 76.5% in group BT), 
which contributed to the reduced VA recorded. How-
ever, none of the patients required cataract surgery 
during the follow up.
According to some authors, lower CMT and 
younger age are positive prognostic factors in 
CRVO10,11. Their study, though, lacks assessment of 
the perfusion status, which significantly affects the 
outcome and prognosis. The ischemic type of occlu-
sion involves a more extensive area of capillary occlu-
sion (i.e. over 10 disc diameter) and carries a graver 
prognosis12. In some cases, the degree of ischemia in-
creases over time and it is responsible for ‘conversion’ 
of non-ischemic to ischemic type of occlusion13. Ap-
proximately one-third of CRVO patients cross from 
non-ischemic to ischemic type within a year14. The 
degree of retinal ischemia is therefore one of the most 
important prognostic factors for visual outcome in 
these patients. The BRAVO and CRUISE data sug-
gest better visual outcome if there is no delay in start-
ing treatment15. It is assumed that there is a larger ex-
tent of undamaged photoreceptors, as well as revers-
ible ischemia in the early course of illness, which is 
susceptible to intravitreal anti-VEGF therapy. Ac-
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cording to the literature, higher macular thickness val-
ues indicate retinal ischemia16, which was also con-
firmed in our study. Better efficacy of the combined 
treatment suggests a more potent action of bevacizum-
ab and triamcinolone on lowering CMT and demands 
further studies. Considering IOP elevation, there was 
no significant elevation or changes of IOP across the 
groups or within any group of patients. The prevalence 
of secondary ocular hypertension or glaucoma after in-
travitreal triamcinolone acetonide (IVTA) administra-
tion varies from 40.4% to 53.3%17. There was no sig-
nificant IOP elevation in the BT and B groups, which 
could be attributed to the lower dose of corticosteroids 
(1 mg IVTA) used in the combined treatment. This 
confirms that the lower dose of corticosteroids (1 mg 
IVTA) is efficient in treating macular edema second-
ary to RVO, with fewer complications compared to 
the usually administered dose of 4 mg IVTA18. No 
signs of intraocular inflammation or infection were 
noted among patients. Only one group T patient with 
ischemic CRVO developed neovascular glaucoma and 
that patient had primary open-angle glaucoma as a 
known risk factor at the time of enrolment in the study. 
Otherwise, none of the patients developed neovascu-
larization of the iris, disc or retina. This confirmed a 
good safety profile of the combined treatment, which 
mandates validation through future studies on a larger 
sample of patients and longer follow up period. Macu-
lar thickness over 250 µ was used as a reapplication 
criterion. The number of applications was lower in the 
BT group, which confirmed higher efficiency and low-
er economic burden of combined therapeutic ap-
proach. The reference books offer equivocal data on the 
number of applications. In the study by Hou et al.18, 
which compared the efficacy of intravitreal bevaci-
zumab and IVTA in macular edema after RVO, the 
mean number of applications was 1.2 of IVTA and 
3.83 of bevacizumab after one-year follow up 
(148.43±130.53 days). The dose of IVTA was 4 mg; 
hence, the lower number of applications could have 
been related to the higher dose of the medication, 
while the safety profile and IOP changes were better 
in our study. Another study assessed the efficacy of 
bevacizumab on the same model of the disease and has 
reported the mean of 8 applications during one-year 
follow up20. This could be due to a shorter interval of 4 
weeks between applications as compared to 6-week 
regimen used in our study. The fewer number of ap-
plications in the BT group in comparison to the results 
of other studies investigating the efficacy of IVTA in 
macular edema after RVO21 confirmed the hypothesis 
of an additive effect of the combination of both drugs. 
It has to be noted that the initial macular thickness 
according to groups was B=325 µm, T=506 µm, and 
BT=620 µm. The final macular thickness which was 
measured after 12 months was on average B=316 µm, 
T=351 µm, and BT=396 µm. The difference was statis-
tically significant between the bevacizumab and com-
bination groups (p=0.022), which confirmed the more 
potent action of the combination of both drugs. Most 
of the patients did not have complete regression of 
macular edema, which was reflected in the mean CMT 
after the third visit. In spite of this, there was certain 
VA improvement in the B and BT groups. This is in 
concordance with the results from the reference books 
and suggests that there are other factors that cause vas-
cular leakage and residual edema other than VEGF22. 
This hypothesis is confirmed by the reports of targeted 
panretinal photocoagulation of the ischemic retinal ar-
eas reducing rebound macular edema23,24.
In conclusion, our study showed that combined 
treatment with bevacizumab and triamcinolone for 
macular edema secondary to RVO may represent a 
novel therapeutic option when compared to a single 
treatment option. It implies a lower rate of adverse 
events and less frequent intravitreal administration of 
drug. However, future studies should include a larger 
number of patients with BRVO to confirm these re-
sults and allow for better harmonization among 
groups. Other registered intraocular medications ap-
proved for this indication should have advantage but 
we find that this represents a reasonable therapeutic 
option which should be considered if they are not 
available due to medico-economic issues. This study 
also confirmed the need of novel combination treat-
ment options to fight macular edema more efficiently.
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Sažetak
KOMBINIRANO LIJEČENJE MAKULARNOG EDEMA UZROKOVANOG OKLUZIJOM  
MREŽNIČNE VENE BEVACIZUMABOM I TRIAMCINOLON ACETONIDOM
M. Vinković, D. Bosnar, E. Tedeschi Reiner, G. De Salvo i S. Matić
Cilj rada bio je utvrditi učinkovitost kombinirane intravitrealne terapije bevacizumabom i triamcinolonom kod makular-
nog edema nastalog kao posljedica okluzije mrežnične vene. Prospektivno randomizirano ispitivanje provedeno je na Odjelu 
za očne bolesti Kliničkoga bolničkog centra Osijek. U ispitivanje je bio uključen 51 ispitanik, koji su podijeljeni u tri skupine 
ovisno o vrsti lijeka koji su primali. Bolesnici u prvoj skupini primali su 1,25 mg bevacizumaba intravitrealno, druga skupina 
ispitanika je primala 1 mg triamcinolona intra vitrealno, a treća skupina je primala kombinaciju 1,25 mg bevacizumaba i 1 mg 
triamcinolona intravitrealno u istom posjetu. Tijekom razdoblja praćenja promatrane su promjene u centralnoj makularnoj 
debljini, vidnoj oštrini, kao i vrijednosti intraokularnog tlaka. Fluoresceinska angiografija primijenjena je za procjenu perfu-
zijskog statusa retine. Skupina koja je primila kombiniranu terapiju s oba lijeka imala je bolji ishod u vidu smanjenja maku-
larne debljine. Nije bilo značajnijeg povišenja očnog tlaka unutar skupina, kao ni usporedbom među skupinama. U skupini 
ispitanika koji su primili kombinaciju oba lijeka zabilježen je pozitivan trend u oporavku vidne oštrine, iako su imali najniže 
ulazne vrijednosti vidne oštrine, najveću vrijednost centralne makularne debljine mjerenu optičkom koherentnom tomo-
grafijom i najduže prosječno trajanje okluzije u odnosu na ostale skupine ispitanika. Zaključno, smanjenje broja injekcija 
kod primjene kombinacije oba lijeka predstavlja ekonomičniji pristup liječenju okluzije mrežnične vene, a također djeluje 
potentnije na sniženje centralne makularne debljine u odnosu na pojedinačnu primjenu svakog lijeka.
Ključne riječi: Okluzija mrežnične vene; Makularni edem; Intravitrealna primjena; Triamcinolon; Bevacizumab
